Morgan Stanley Immunity Bio, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,373,570 shares of IBRX stock, worth $7.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,373,570

Previous 2,972,269 13.5%

Holding current value

$7.02 Million

Previous $7.85 Million 5.76%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.24 - $3.01 $898,914 - $1.21 Million	401,301 Added 13.5%	3,373,570 $8.3 Million
Q2 2025 Aug 15, 2025	BUY	$1.89 - $3.44 $2.04 Million - $3.71 Million	1,077,135 Added 56.84%	2,972,269 $7.85 Million
Q1 2025 May 15, 2025	SELL	$2.32 - $3.9 $4.9 Million - $8.23 Million	-2,110,680 Reduced 52.69%	1,895,134 $5.7 Million
Q4 2024 Feb 14, 2025	BUY	$2.56 - $6.17 $4.5 Million - $10.9 Million	1,758,922 Added 78.28%	4,005,814 $10.3 Million
Q3 2024 May 14, 2025	BUY	$3.32 - $6.7 $5.57 Million - $11.2 Million	1,678,491 Added 295.3%	2,246,892 $8.34 Million

Q3 2024 Nov 14, 2024	BUY	$3.32 - $6.7 $5.57 Million - $11.2 Million	1,678,491 Added 295.3%	2,246,892 $8.34 Million
Q2 2024 May 14, 2025	SELL	$4.82 - $9.15 $16.6 Million - $31.5 Million	-3,437,413 Reduced 85.81%	568,401 $3.59 Million
Q2 2024 Oct 17, 2024	SELL	$4.82 - $9.15 $270,884 - $514,230	-56,200 Reduced 9.0%	568,401 $3.59 Million
Q2 2024 Aug 14, 2024	SELL	$4.82 - $9.15 $270,884 - $514,230	-56,200 Reduced 9.0%	568,401 $3.59 Million
Q1 2024 Oct 17, 2024	BUY	$3.23 - $6.17 $181,526 - $346,754	56,200 Added 9.89%	624,601 $3.35 Million
Q1 2024 Aug 16, 2024	BUY	$3.23 - $6.17 $80,372 - $153,528	24,883 Added 4.15%	624,601 $3.35 Million
Q1 2024 May 15, 2024	BUY	$3.23 - $6.17 $80,372 - $153,528	24,883 Added 4.15%	624,601 $3.35 Million
Q4 2023 Aug 16, 2024	BUY	$1.25 - $5.21 $39,146 - $163,161	31,317 Added 5.51%	599,718 $3.01 Million
Q4 2023 Feb 13, 2024	BUY	$1.25 - $5.21 $252,271 - $1.05 Million	201,817 Added 50.72%	599,718 $3.01 Million
Q3 2023 Nov 15, 2023	BUY	$1.29 - $3.1 $60,957 - $146,487	47,254 Added 13.48%	397,901 $672,000
Q2 2023 Aug 14, 2023	SELL	$1.53 - $6.41 $341,372 - $1.43 Million	-223,119 Reduced 38.89%	350,647 $974,000
Q1 2023 May 15, 2023	BUY	$1.35 - $4.78 $39,970 - $141,526	29,608 Added 5.44%	573,766 $1.04 Million
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.77 $424,799 - $661,124	-97,655 Reduced 15.22%	544,158 $2.76 Million
Q3 2022 Nov 14, 2022	SELL	$3.65 - $6.43 $1.23 Million - $2.17 Million	-336,830 Reduced 34.42%	641,813 $3.19 Million
Q2 2022 Oct 27, 2022	SELL	$2.68 - $6.14 $254,267 - $582,538	-94,876 Reduced 8.84%	978,643 $3.64 Million
Q2 2022 Aug 15, 2022	SELL	$2.68 - $6.14 $254,267 - $582,538	-94,876 Reduced 8.84%	978,643 $3.64 Million
Q1 2022 Oct 27, 2022	BUY	$5.05 - $7.53 $479,123 - $714,416	94,876 Added 9.69%	1,073,519 $6.02 Million
Q1 2022 May 13, 2022	BUY	$5.05 - $7.53 $3.24 Million - $4.82 Million	640,695 Added 148.03%	1,073,519 $6.02 Million
Q4 2021 Feb 14, 2022	SELL	$5.67 - $10.18 $367,983 - $660,682	-64,900 Reduced 13.04%	432,824 $2.63 Million
Q3 2021 Nov 15, 2021	BUY	$9.17 - $14.24 $4.56 Million - $7.09 Million	497,724 New	497,724 $4.85 Million

Others Institutions Holding IBRX

# of Institutions

297

Shares Held

137M

Call Options Held

2.59M

Put Options Held

3.35M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $833M
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account